

PREGNANCY AND MULTIPLE SCLEROSIS

The initial results from a Brazilian database

Yara Dadalti Fragoso¹, Alessandro Finkelsztein², Elizabeth Regina Comini-Frota³,
Paulo Diniz da Gama⁴, Anderson Kuntz Grzesiuk⁵, Jussara Mathias Netto Khouri⁶,
Soniza Vieira Alves-Leon⁷, Rogério de Rizo Morales⁸,
Marco Aurélio Lana-Peixoto⁹, Cristiane Franklin da Rocha⁹

Abstract – Purpose: Pregnancy management poses an extra challenge to physicians and their multiple sclerosis (MS) patients. There are few papers reporting databases on the subject. **Method:** Brazilian database from nine MS clinical and research units, with complete data on 47 pregnant women (49 pregnancies). **Results:** Despite relatively high exposure to MS medications, no birth defects were reported. Low birth weight and prematurity were similar to those for developing countries. Three complications may have been associated with these medications, while three others were considered to be of purely obstetric nature. **Conclusion:** Our results confirm previous findings on lower relapse rate during pregnancy and add to the present literature informing on data related to drug exposure.

KEY WORDS: multiple sclerosis, pregnancy, prematurity, low birth weight, obstetric complications, interferon beta, glatiramer acetate.

Gravidez e esclerose múltipla: resultados preliminares de base de dados Brasileira

Resumo – Propósito: O manejo da gravidez cria um desafio extra aos médicos e aos pacientes com esclerose múltipla (EM). Existem poucos trabalhos relatando bases de dados neste tema. **Método:** Base de dados brasileira de nove centros clínicos e de pesquisa na EM, com dados completos de 47 mulheres grávidas (49 gestações). **Resultados:** Apesar da exposição a drogas para EM ter sido relativamente alta, não foram registradas malformações. Baixo peso e prematuridade foram semelhantes àqueles de países em desenvolvimento. Três complicações podem ter sido associadas a drogas, enquanto outras três foram consideradas como sendo de natureza puramente obstétrica. **Conclusão:** Nossos resultados confirmam os achados de menor taxa de surtos na gestação e adicionam dados relacionados a exposição a drogas, na literatura atual.

PALAVRAS-CHAVE: esclerose múltipla, gravidez, prematuridade, baixo peso, complicações obstétricas, interferon beta, acetato de glatirâmer.

Multiple sclerosis (MS) is more prevalent in women of childbearing age, posing an extra challenge for management of this chronic neurological disease. Drugs used for treating MS patients include a variety of immunomod-

ulators and immunosuppressive agents, many of them considered to carry high risk if used during pregnancy. Data on MS and pregnancy are still sparse and controversial. However, since the report by Confravreux et al.¹ of low-

¹MS Reference Center, Coastal Region of São Paulo, SP, DRS IV and Universidade Metropolitana de Santos, Santos SP, Brazil; ²MS Reference Center, Hospital de Clínicas de Porto Alegre, Porto Alegre RS, Brazil; ³Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte MG, Brazil; ⁴Medical School, Pontifícia Universidade Católica de São Paulo, Campus Sorocaba, Sorocaba SP, Brazil; ⁵Instituto Neurológico e da Coluna Vertebral / Hospital Santa Rosa, Cuiabá MT, Brazil; ⁶Medical School, Pontifícia Universidade Católica do Paraná (PUCPR) and Universidade Positivo, Curitiba PR, Brazil; ⁷Universidade Federal do Estado do Rio de Janeiro, Hospital Universitário Clementino Fraga Filho, Research Unit on Idiopathic Inflammatory Demyelinating Diseases of the CNS, Rio de Janeiro RJ, Brazil; ⁸Universidade Federal de Uberlândia, Uberlândia MG, Brazil; ⁹CIEM, Investigation Center for MS, Universidade Federal de Minas Gerais, Belo Horizonte MG, Brazil.

Received 10 April 2009. Accepted 15 June 2009.

Dra. Yara Dadalti Fragoso – Department of Neurology / Medical School / UNIMES - Rua da Constituição 374 - 11015-470 Santos SP - Brasil. E-mail: yara@bsnet.com.br

Table 1. Data on 47 women with MS who became pregnant over the last five years (49 pregnancies).

	Mean (±SD)
Age at start of MS symptoms (years)	23.3 (5.6)
Age at MS diagnosis (years)	25.6 (6.2)
Age at start of pregnancy (years)	28.4 (5.4)
EDSS at start of pregnancy	1.36 (1.5)
Relapse rate in the year prior to pregnancy	1.37 (1.9)
Relapse rate during pregnancy	0.29 (0.6)*
Relapse rate up to 6 months after delivery	0.86 (1.1)
Gestational age at delivery (weeks)	37.6 (2.3)
Newborn weight (g)	2827 (619)
Breastfeeding period (months)	5.4 (6.6)
None or one previous pregnancy	40
Early exposure to interferon beta	17
Early exposure to glatiramer acetate	15
Early exposure to other MS drugs	2
Exposure to MS drugs during pregnancy	15
No exposure to MS drugs before or during pregnancy	15
Obstetric complications probably not drug-related	3
Complications that may have been due to drug exposure	3

*p=0.002 in relation to both pre and post pregnancy periods

er risk of relapses during pregnancy, all researchers seem to have agreed with this point. In fact, such relapse rate reduction is typical of the T-cell regulation favored by pregnancy-specific glycoproteins², alpha-fetoprotein³, estrogens⁴ and estriol⁵ and expression of chemokine receptors⁶. During pregnancy, both the inherent reduction in relapses and the uncertainty about the safety of drugs used for MS, encourage physicians not to prescribe any medications. However, many women using MS drugs become pregnant while taking these medications, even if they stop any treatment as soon as they realize they are pregnant. Some physicians may, even when aware of the risks, consider it necessary to continue with some medications for their patients, and follow the recommendations of the Food and Drug Administration (FDA).

The FDA classification for MS immunomodulatory and immunosuppressive drugs specifies that there are no safe Class A drugs. Class B drugs include immunoglobulin and glatiramer acetate. Class C includes beta-interferons, mitoxantrone and corticosteroids. Drugs with evidence of fetal risk, where the risk and benefit should be carefully assessed, include azathioprine and cyclophosphamide. Methotrexate is considered to be very high risk (Class X) and should not be used for potentially fertile women.

The relative rarity of data on pregnancy and MS has encouraged our study⁷.

METHOD

Over a period of ten months in 2008, MS researchers in Brazil were invited to send data from the last five years on their cases of pregnancy in MS patients. Those who showed interest in this study received, by e-mail, a specific Excel file. Two of the re-

Table 2. Data on potential effects of different MS drugs used at any time during pregnancy.

Outcome	No drug exposure (n=15)	Interferon beta (n=17)	Glatiramer acetate (n=15)	Corticosteroids (n=8)	Immuno globulin (n=3)	Methotrexate (n=1)	Combination (n=11)
Low birth weight	1	1	1	3	0		1
Prematurity	1	2	1	1	0		2
Birth defects	0	0	0	0	0		0
Neonatal death	0	0	0	0	0		1 [PNR]
Abortion	0	0	1 [PNR]	0	1		0
Delayed intrauterine growth	0	1	0	0	0		0
Neonatal jaundice	1	0	0	0	0		0
Shoulder dystocia	0	0	1 [PNR]	0	0		0
Twin pregnancy	0	0	0	0	0		1 [PNR]

PNR: probably not related (according to obstetrician).

searchers (AF, YDF) received the returned files and (AF) analyzed the data. The present paper was written by one of the researchers (YDF) and its contents were approved by all participants prior to submission. This work was not carried out at a single institution and it was undertaken on the authors' own initiative, working without any financial support. Authorization from Ethics Committees and patients' consent were individually obtained by the authors, in accordance with the regulations of their workplaces.

The Excel file included each patient's demographic data, history and characteristics of MS, data on clinical and neurological conditions, time of each pregnancy, medications in use at any gestational stage, number and timing of relapses, birth outcome and breastfeeding details.

The t-test was used to calculate continuous data and the chi-square test, for categorical data. Correlations were assessed using the ANOVA, Pearson and Spearman tests. Results were considered to be significant when $p < 0.05$. SPSS version 11.5 was used for all the analyses.

RESULTS

Complete data from 47 women (49 pregnancies) were received and analyzed. A summary of the demographic and gestational data is presented in Table 1. Regular treatment at the time of pregnancy diagnosis was: interferon-beta (17 cases), glatiramer acetate (15 cases), methotrexate (1 case) and corticosteroids (1 case), while 15 patients were not receiving any regular medication. Glatiramer acetate was continuously administered during pregnancy in 12 patients, in accordance with their physicians' decision and discretion. Although decreased, postpartum relapse rate in these cases were not significantly reduced in patients who used drugs throughout pregnancy ($p = 0.41$).

There were no cases of fetal malformation. Obstetric complications consisted of one neonatal death (hospital infection), one abortion (polycystic ovaries and obesity) and one shoulder dystocia (baby $> 3,500$ g).

The following complications might have been drug-related. One case of abortion was temporally related to a relapse and the use of immunoglobulin. It cannot be ruled out that one case of hemorrhage and one case of delayed intrauterine growth might have been related to MS or its treatment (corticosteroids and interferon-beta 1a 22 mcg three times a week, at start of pregnancy, respectively).

One case of neonatal jaundice was reported in a patient without drug exposure. There was one case of twins, born without complications, despite one sibling's low weight. Low birth weight or prematurity rates were similar to those for developing countries (7 cases, 14.8%). Both low birth weight and prematurity were observed in three of these babies. These cases could not be correlated to any drugs, EDSS or MS duration. The only patient using methotrexate, who became pregnant despite counseling and the use of birth control pills, did not present any

complication during or after pregnancy, and her normal child is now two years old.

A summary of data on the potential effect of drugs is presented in Table 2.

DISCUSSION

This is the first Brazilian collaborative study on pregnancy and MS. The present work reports on one of the largest series of cases (49 pregnancies) recorded in proper databases in the world⁷⁻¹². Only pregnancy cases from Canada (n=16)⁷, Sweden⁸ (n=69), Spain⁹ (n=88), Finland¹⁰ (n=42), Italy¹¹ (n=38) and Germany¹² (n=88) have been previously reported in the literature with a similar methodology.

Our results showed no correlation among parameters in early pregnancy (different drugs, EDSS and time of disease) and poor gestational outcome (low birth-weight, prematurity, birth defects and drug-related complications). The lower relapse rate during pregnancy was in accordance with expected results¹. No significant increase in relapse rate was observed in the postpartum period. Our patients were of relatively young age, with low EDSS at the beginning of pregnancy, nearly half of them in their first pregnancy, and only a small number of relapses in the year preceding pregnancy. These findings corroborate the idea, already noted by others^{13,14}, that perhaps women in better clinical condition have increased propensity to maternity, at the same time that those using more aggressive cytotoxic treatments may present impaired fertility¹⁵. The use of FDA Class B drugs during pregnancy did not significantly alter the postpartum relapse rate. This finding further corroborates the concept that there is no indication for continuous use of medication during gestation, and that medical prescription should be used only in very particular cases. However, it must be considered that only the most aggressive forms of MS were treated during pregnancy in Brazil, and the similar relapse rate in those who used immunomodulators must be further assessed. Data collection in Brazil continues, assessing MS and pregnancy parameters, as well as drug exposure. Physicians who are interested in joining the database should send an e-mail to lampreg@yahoo.com indicating their willingness to participate in the study.

REFERENCES

1. Confravreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. *N Engl J Med* 1998;339:283-291.
2. Bebo BF Jr, Dveskler GS. Evidence that pregnancy specific glycoproteins regulate T-Cell function and inflammatory autoimmune disease during pregnancy. *Curr Drug Targets Inflamm Allergy* 2005;4:231-237.
3. Murgita RA, Andersson LC, Sherman MS, Bennich H, Wigzell H. Effects of human alpha-fetoprotein on human B and T lymphocyte proliferation in vitro. *Clin Exp Immunol* 1978;33:347-356.
4. Soldan SS, Retuerto AIA, Sicotte NL, Voskuhl RR. Immunomodulation in multiple sclerosis patients treated with the pregnancy hormone estriol. *J Immunol* 2003;171:6267-6274.

5. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. *Ann Neurol* 2002;52:421-428.
6. Lopez C, Comabella M, Tintore M, Sastre-Garriga J, Montalban X. Variations in chemokine receptor and cytokine expression during pregnancy in multiple sclerosis patients. *Mult Scler* 2006;12:421-427.
7. Sandberg-Wollheim M, Frank D, Goodwin TM, et al. Pregnancy outcomes during treatment with interferon beta-1a in patients with multiple sclerosis. *Neurology* 2005;65:802-806.
8. Boskovic R, Wide R, Wolpin J, Bauer DJ, Koren G. The reproductive effects of beta interferon therapy in pregnancy: a longitudinal cohort. *Neurology* 2005;65:807-811.
9. De Las Heras V, De Andrés C, Téllez N, Tintoré M, EMPATIE Study Group. Pregnancy in multiple sclerosis patients treated with immunomodulators prior to or during part of the pregnancy: a descriptive study in the Spanish population. *Mult Scler* 2007;13:981-984.
10. Saraste M, Vaisanen S, Alanen A, Airas L, Finnish Multiple Sclerosis and Pregnancy Study Group. *Gen Med* 2007;4:45-55.
11. Patti F, Cavallaro T, Lo Fermo S, et al. Is in utero early-exposure to interferon beta a risk factor for pregnancy outcomes in multiple sclerosis? *J Neurol* 2008;255:1250-1253.
12. Hellwig K, Brune N, Muller T, Schimrigk S, Schwodiauer V. Reproductive counselling, treatment and course of pregnancy in 73 German MS patients. *Acta Neurol Scand* 2008;118:24-28.
13. Argyriou AA, Makris N. Multiple sclerosis and reproductive risks in women. *Reprod Sci* 2008;15:755-764.
14. Lee M, O'Brien P. Pregnancy and multiple sclerosis. *J Neurol Neurosurg Psychiatry* 2008;79:1308-1311.
15. Cocco E, Sardu C, Gallo P, et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. *Mult Scler* 2008;14:1225-1233.